Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Dec 4, 2015

SGI-DNA BioXp 3200 System Cloning Module

SGI-DNA (Synthetic Genomics) has launched beta testing of the BioXp 3200 System Cloning Module, which adds the capability to assemble and simultaneously deliver up to 24 DNA clones from custom DNA sequences submitted electronically to the BioXp System. The BioXp System is a benchtop genomic workstation that generates high-quality DNA from custom-designed reagents. The system's workflow gives customers the ability to focus on scientific discovery and analytics by releasing users from traditional hands-on, time-intensive, tedious DNA cloning methods, the company said in a statement.

AltheaDx Oncology Panel AOP50

AltheaDx has launched AltheaDx Oncology Panel AOP50, a CLIA-validated next-generation sequencing assay designed for multiple drug and companion diagnostic development programs. The assay is based on Thermo Fisher Scientific's Oncomine Focus Assay and uses biomarkers that have been selected using the Oncomine Knowledgebase, the company said in a statement. The AOP50 assay allows concurrent analysis of DNA and RNA from solid tumors, sequencing of 35 hotspot genes, and sequencing of 23 fusion genes in a single workflow on the Ion PGM System. It also enables gene fusion transcript detection and reduces the complexity of performing alternate fusion detection methods such as fluorescence in situ hybridization. Leveraging the low-sample input requirement from formalin-fixed paraffin-embedded tissue for the Ion AmpliSeq technology, AOP50 enables accurate and reliable analysis of sequences from different tumor sample types, including small biopsies and fine needle aspirates.

Abcodia ROCA Ovarian Cancer Test

Abcodia has launched its ROCA ovarian cancer test in five US states: Arizona, Illinois, Massachusetts, New Jersey, and Texas.

The test, available as a service from the company's testing laboratory, is designed to aid in the early detection of ovarian cancer through the analysis of a number of clinical variables such as age, menopausal status, and serial blood measurements of the biomarker protein CA125. The assay is the first step in a multimodal assessment for ovarian cancer and is to be used to help physicians assess whether a woman should undergo additional testing, including a transvaginal ultrasound scan of the ovaries.

Abcodia said that the test is intended for post-menopausal women between 50 and 85 years old and with no known ovarian cancer risk factors; or women 35 to 85 who are considered to be at high risk of ovarian cancer due to a family history of ovarian or breast cancer, or a mutation in specific genes such as BRCA1, BRCA2, or Lynch syndrome genes.

The test is already being used in the UK by private clinics and will become available in additonal US states throughout 2016, Abcodia said.

For more on the ROCA test, click here.

For more new products and services, please visit the New Products page on our website.